Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents - Wikidata - awgldk - TriplyDB

Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents

Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents

http://www.wikidata.org/entity/Q35882189

about

Single cell analysis of drug distribution by intravital imaging Advancing biomedical imaging Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent.Initial evaluation of Cu-64 labeled PARPi-DOTA PET imaging in mice with mesothelioma.Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors In vivo imaging of multidrug resistance using a third generation MDR1 inhibitor.Single cell resolution in vivo imaging of DNA damage following PARP inhibition Imaging the DNA damage response with PET and SPECT Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.Red Si-rhodamine drug conjugates enable imaging in GFP cells.Efficient acid-catalyzed (18) F/(19) F fluoride exchange of BODIPY dyes.PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin.Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo.In vivo imaging of specific drug-target binding at subcellular resolution.Radioiodinated PARP1 tracers for glioblastoma imaging.Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma.Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics.[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models.Efficient (18)F-Labeling of Synthetic Exendin-4 Analogues for Imaging Beta Cells Bioorthogonal approach to identify unsuspected drug targets in live cells.Cancer subclonal genetic architecture as a key to personalized medicine.Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis.Expanding room for tetrazine ligations in the in vivo chemistry toolbox.The inverse electron demand Diels-Alder click reaction in radiochemistry.Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy.Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor.PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.A photoactivatable drug-caged fluorophore conjugate allows direct quantification of intracellular drug transport.Molecular Imaging of PARP.Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.Detection and Delineation of Oral Cancer With a PARP1-Targeted Optical Imaging Agent.Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration Measurement of drug-target engagement in live cells by two-photon fluorescence anisotropy imaging.Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models.Fluorescence anisotropy imaging in drug discovery.PARP1-Targeted Radiotherapy in Mouse Models of Glioblastoma.An 18F-Labeled Poly(ADP-ribose) Polymerase Positron Emission Tomography Imaging Agent.

P2860

Q21133568-22C2AC8A-F333-474C-B38C-57C4030FA05F Q26776383-6A831F49-EB8D-4EA0-A544-A922C721B0E6 Q27347956-235CA5E8-84CE-4539-92EC-5BA031B88D48 Q30252194-16DDD374-E9CD-4AAA-B4D9-877FBC820873 Q30575798-F627AD0C-CD55-46A8-AA06-FCA209E7148E Q30583710-26080360-0624-4F5E-B869-F480CD2F1A6A Q30650918-9EE3BB46-0263-485B-A503-196492A480B8 Q33581909-6789C16B-4926-4436-B3CB-B7EB46E44458 Q33607384-0C08213F-B6B0-4380-B8E1-5A47B9EA4B57 Q33640944-FD3A1CDA-4890-4339-8D23-832F3CECEC56 Q34092219-A10483F9-AB6C-43A7-8DE8-9E402010A215 Q34346449-CAE2E828-312E-41EA-9B94-D5579CC81263 Q34446806-DDFB210F-47B8-42B1-BDED-7AAD460B3CC1 Q34592125-80A61211-2FE6-49BA-9F33-E7B0CB350F00 Q35184841-9A659BFB-4E3A-4700-8C8E-6F8CB0178F7C Q35764111-686AAE13-D9A1-4671-8043-3BB93757F05B Q35903928-7A5B5EF5-1FFA-469D-B15D-B75EA3A15817 Q36172457-DA8942F5-F930-4317-9A84-2E753BCB6156 Q36418274-2DDBFAFA-8D7C-441D-B5AE-6B1E29973C87 Q36568348-6EA322A0-E63B-4043-AEE8-68A0313AF3EC Q36827491-BEDD0EE9-33C9-4449-9D2E-5D7BEAB80E78 Q37134464-97836FDC-FB51-46ED-89CB-B9AB2B1D9B99 Q37376761-715985A7-ACCC-447C-8908-3E2C0BFED924 Q37448116-6D6170A9-6B58-4C81-A8BD-3A88B866D4E9 Q37724107-8452130C-B608-4E4B-BC08-65ACA3031823 Q37728469-7EC958A0-E9D2-44E8-82A5-D8E717063AC4 Q38172061-56452877-8F13-42D1-8D2A-68EA8F5BDFB5 Q38206206-847A81D9-2EBF-412B-AF02-D9AFCF8FC223 Q38938436-7616EDE4-D3AC-47D7-8EA8-B463AC9D680E Q39007680-561ED7C8-A045-4C33-A7A5-296FF9C52445 Q39077308-BA73214A-DDA3-438A-86D3-304CDB31971E Q39284725-4EA2D1D6-9669-451D-9407-3F15512BE182 Q41276800-1EA27332-120A-440D-9FF9-EA0CB9C89897 Q41603260-B0D7DA7B-9D94-4273-ABB3-39CB812131D4 Q41879186-189CF2CE-ADD2-4B2F-B0F3-0AA05EBD0205 Q47949142-335E9219-9254-455A-98F9-5188D441A400 Q48347188-F595ED58-1767-4C94-95F1-576F90E56E00 Q50150511-996DD023-76D4-4BFE-B353-2DFA798851C4 Q52639515-C9903EEE-2BDD-4BD6-89AE-261F496C24BC Q55326030-4156FE52-432F-48FC-87AA-0B1709D78ED9

P2860

Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents

http://www.wikidata.org/entity/Q35882189

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Imaging therapeutic PARP inhib ...... loped companion imaging agents

@ast

Imaging therapeutic PARP inhib ...... loped companion imaging agents

@en

type

label

Imaging therapeutic PARP inhib ...... loped companion imaging agents

@ast

Imaging therapeutic PARP inhib ...... loped companion imaging agents

@en

prefLabel

Imaging therapeutic PARP inhib ...... loped companion imaging agents

@ast

Imaging therapeutic PARP inhib ...... loped companion imaging agents

@en

P1433

Q35882189-E2C5FD5D-1BCE-4374-B13B-1E99305854FB

P1476

Q35882189-848263DC-9649-4871-89A6-94647C2BF6F3

P2093

Q35882189-94AE303A-05D6-40F6-A88F-160AB3FBED41

Q35882189-E28E24D2-2297-40D3-A366-50B4539B8E23

Q35882189-F2C59E2C-F13C-496F-915E-3B2621940A98

Q35882189-FF3AA80D-3DC2-44CF-8613-67D3F9188B31

P2860

Q35882189-02FD7270-4581-4233-A8BA-3FA359372CF5

Q35882189-0B1EF581-8A90-46DF-9DB9-7E80C701AEC5

Q35882189-1BDB8A8D-B836-4E75-8A89-57776FF53E61

Q35882189-1E9CC245-C540-499A-B1B4-95C10B269BE7

Q35882189-20382C72-6C99-483B-B158-BB33B698A412

Q35882189-26D096BF-E8EC-4734-86ED-606E64E041C1

Q35882189-362681F6-20E2-4219-806A-CDC1038FACB7

Q35882189-37285F81-DCDF-46DB-A3A7-144DCD8DFA80

Q35882189-49EDC4E2-21C4-49EB-B5E1-33C49B7210D9

Q35882189-4E7A2EBF-3AF5-497A-959B-2BCBF50AC271

P304

Q35882189-FFA34504-E4B8-4A0D-9158-69967673C9E2

P31

Q35882189-E94EB5B4-ED30-43DF-90E2-DB091F22B395

P356

Q35882189-976D3D01-A1EE-4546-BADB-40A549A89609

P433

Q35882189-492DC6BB-0DF0-49C2-890F-D281500671A0

P478

Q35882189-EBF5A2CA-F167-4A70-A2EE-B7CFD9B7DE74

P50

Q35882189-0B03B28E-CFAA-4C9D-BF6F-BF4ED95CCF60

Q35882189-4640FAEA-51D2-47B1-B22E-D3C402BC6528

Q35882189-4AA807AB-0943-4DA7-9654-9422D4A73FF1

Q35882189-E2AAD5E6-4BBC-4399-A581-0D7A051765A5

P577

Q35882189-FF8AF8C4-B3EB-4A8F-BA0A-C3B12D0D680D

P5875

Q35882189-AA71167B-9C07-4A74-AFE8-DA0AE4066936

P698

Q35882189-DEBBDCBE-5EA3-4401-8C30-B7516B2486F4

P932

Q35882189-D0FFE1FC-8ECE-4320-841B-1969077FC0AE

P356

P1433

P1476

Imaging therapeutic PARP inhib ...... loped companion imaging agents

@en

P2093

Adeeti Ullal

http://www.w3.org/2001/XMLSchema#string

Edmund J Keliher

http://www.w3.org/2001/XMLSchema#string

Jessica Lacy

http://www.w3.org/2001/XMLSchema#string

Katherine S Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Understanding the Warburg effect: the metabolic requirements of cell proliferation

Intravital imaging.

A high precision survey of the molecular dynamics of mammalian clathrin-mediated endocytosis

Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

PARP inhibition: PARP1 and beyond

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

Dynamic imaging of cancer growth and invasion: a modified skin-fold chamber model.

P304

169-177

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/NEO.12414

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Claudio Vinegoni

Rainer H Kohler

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223977878

http://www.w3.org/2001/XMLSchema#string

P698

22496617

http://www.w3.org/2001/XMLSchema#string

P932

3323895

http://www.w3.org/2001/XMLSchema#string